MedPath

Trial of Dacarbazine With or Without Genasense in Advanced Melanoma

Phase 3
Completed
Conditions
Melanoma
Interventions
Registration Number
NCT00518895
Lead Sponsor
Genta Incorporated
Brief Summary

This study is being performed to prospectively determine whether dacarbazine plus Genasense is significantly better than dacarbazine plus placebo in chemotherapy-naive patients with advanced melanoma and low baseline LDH (LDH less than or equal to 0.8 times the upper limit of normal). LDH is a biomarker strongly associated with improved outcomes in a recent trial of dacarbazine plus Genasense.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
300
Inclusion Criteria
  • Histologically confirmed diagnosis of melanoma
  • Progressive disease that is not surgically resectable, or metastatic Stage IV
  • Low-normal LDH, defined as ≤ 0.8 times the upper limit of normal
  • No prior chemotherapy
  • Measurable disease
  • ECOG performance status ≤ 1
  • At least 4 weeks and recovery from effects of major prior surgery or other therapy, including immunotherapy, radiation therapy, or cytokine, biologic or vaccine therapy
  • Prior immunotherapy allowed
  • Adequate organ function
Exclusion Criteria
  • Prior cytotoxic chemotherapy, including regional perfusion, or prior Genasense treatment
  • Primary ocular or mucosal melanoma
  • Bone-only metastatic disease
  • History or presence of brain metastasis or leptomeningeal disease
  • Significant medical disease other than cancer
  • Organ allograft

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Adacarbazine plus GenasenseDacarbazine with Genasense
Bdacarbazine plus placeboDacarbazine with placebo
Primary Outcome Measures
NameTimeMethod
Progression-free survival and overall survivalEvery 42 days from date of randomization during protocol therapy
Secondary Outcome Measures
NameTimeMethod
Response rate, durable response rate, duration of response, safetyResponse and progression every 42 days from date of randomization during protocol therapy

Trial Locations

Locations (76)

Dana Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Texas Oncology - Sammons Cancer Center

🇺🇸

Dallas, Texas, United States

MD Anderson Cancer Center at University of Texas

🇺🇸

Houston, Texas, United States

Princess Margaret Hospital

🇨🇦

Toronto, Ontario, Canada

Hematology Oncology Centers of the Northern Rockies

🇺🇸

Billings, Montana, United States

The West Clinic

🇺🇸

Memphis, Tennessee, United States

Medical University of Vienna, Vienna General Hospital

🇦🇹

Wien, Austria

Wielkopolskie Centrum Onkologii

🇵🇱

Poznan, Poland

The Royal Marsden Hospital

🇬🇧

London, United Kingdom

Klinik und Poliklinik fur Hautkrankheiten

🇩🇪

Munster, Germany

Cancer Care Associates, Site 1

🇺🇸

Tulsa, Oklahoma, United States

Istituto Nazionale dei Tumori "G. Pascale"

🇮🇹

Napoli, Italy

Azienda Ospedaliera Universitaria di Siena

🇮🇹

Siena, Italy

Hopital Sainte Marguerite

🇫🇷

Marseille, France

San Diego Pacific Oncology and Hematology Associates Inc.

🇺🇸

Encinitas, California, United States

Hospital Germans Trias I Pujol

🇪🇸

Barcelona, Spain

University of South Alabama Hospital, Mitchell Cancer Institute

🇺🇸

Mobile, Alabama, United States

Universitatsklinik fur Dermatologie und Venerologie, Medizinische Universitat Innsbruck

🇦🇹

Innsbruck, Austria

Szpital Akademii Medycznej w Gdansku

🇵🇱

Gdansk, Poland

University Hospital Zurich

🇨🇭

Zurich, Switzerland

Ospedale San Salvatore

🇮🇹

Coppitto-L'Aquila, Italy

Universitatsklinikum Giessen und Marburg GmbH, Klinik fur Dermatologie und Allergologie

🇩🇪

Marburg, Germany

Hautklinik Universitat Tubingen

🇩🇪

Tubingen, Germany

Clinica Universitaria de Navarra

🇪🇸

Navarra, Spain

Klinikum Quedlinburg

🇩🇪

Quedlinburg, Germany

Hospital Gregorio Maranon

🇪🇸

Madrid, Spain

Hospital Clinic I Provincial de Barcelona

🇪🇸

Barcelona, Spain

Thomas Jefferson University Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

Charles University, Dermatology Department

🇨🇿

Prague, Czech Republic

Morristown Memorial - Atlantic Healthcare System

🇺🇸

Morristown, New Jersey, United States

Helios Vogtland-Klinikum Plauen

🇩🇪

Plauen, Germany

Istituto Nazionale dei Tumori

🇮🇹

Milano, Italy

Siouxland Hematology Oncology Associates

🇺🇸

Sioux City, Iowa, United States

CHU Hotel Dieu

🇫🇷

Nantes, France

Dermatologische Klinik und Poliklinik

🇩🇪

Regensburg, Germany

Universitatsklinikum Mannheim

🇩🇪

Mannheim, Germany

Weston Park Hospital

🇬🇧

Sheffield, United Kingdom

IFO Instituto Regina-Elena - IRCCS

🇮🇹

Rome, Italy

Istituto Dermopatico dell'Immacolata

🇮🇹

Rome, Italy

Nottingham University Hospitals NHS Trust, City Campus

🇬🇧

Nottingham, United Kingdom

London Regional Cancer Program

🇨🇦

London, Ontario, Canada

Cancer Care Associates

🇺🇸

Oklahoma City, Oklahoma, United States

Landesklinikum St. Polten

🇦🇹

St. Polten, Austria

St. Luke's Cancer Center

🇺🇸

Bethlehem, Pennsylvania, United States

Calvary Mater Newcastle

🇦🇺

Newcastle, New South Wales, Australia

Hopital Saint-Andre

🇫🇷

Bordeaux, France

Westmead Hospital

🇦🇺

Westmead, New South Wales, Australia

CHU Saint Jacques

🇫🇷

Besancon, France

Sydney Cancer Center, Royal Prince Alfred Hospital

🇦🇺

Camperdown, New South Wales, Australia

CHU de Dijon, Hopital du Bocage Sud

🇫🇷

Dijon, France

CHU Ambroise Pare

🇫🇷

Boulogne-Billancourt, France

CHRU de Lille, Hopital Claude Huriez

🇫🇷

Lille, France

Hopital Saint Eloi

🇫🇷

Montpellier, France

Hopital de l'Hotel Dieu

🇫🇷

Lyon, France

Hopital Robert Debre

🇫🇷

Reims, France

CHU de Grenoble, Hopital Albert Michallon

🇫🇷

Grenoble, France

Centre Hospitalier du Mans

🇫🇷

Le Mans, France

CHU CH Nicolle

🇫🇷

Rouen, France

Institut Gustave Roussy

🇫🇷

Villejuif, France

Hopital Saint-Louis

🇫🇷

Paris, France

Vivantes Klinikum Neukoln, Klinik fur Dermatologie und Venerologie

🇩🇪

Berlin, Germany

Charite Universitatsmedizin Berlin

🇩🇪

Berlin, Germany

Vivantes Klinikum im Friedrichshain

🇩🇪

Berlin, Germany

Helios Klinikum Erfurt

🇩🇪

Erfurt, Germany

Klinik fur Dermatologie und Allergologie der Ruhr-Universitat Bochum

🇩🇪

Bochum, Germany

Klinik fur Dermatologie, Allergologie und Venerologie, Universitatsklinikum Essen

🇩🇪

Essen, Germany

Universitatsklinikum Freiburg

🇩🇪

Freiburg, Germany

Klinikum der Friedrich-Schiller-Universitat Jena

🇩🇪

Jena, Germany

Hautklinik Linden

🇩🇪

Hannover, Germany

Universitatklinikum A. o. R.

🇩🇪

Leipzig, Germany

Hospital of the University of Schleswig-Holstein

🇩🇪

Lubeck, Germany

Klinik und Poliklinik fur Dermatologie und Venerologie

🇩🇪

Koln, Germany

Universitats-Hautklinik Mainz

🇩🇪

Mainz, Germany

Redwood Regional Medical Group, Inc.

🇺🇸

Santa Rosa, California, United States

Christie Hospital

🇬🇧

Manchester, United Kingdom

Guy's Hospital

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath